Boosting the immune system to combat cancer The primary killer cells crucial in the immune response are cytotoxic T cells, which identify specific antigen peptides bound to MHC molecules

·         Boosting the immune system to combat cancer The primary killer cells crucial in the immune response are cytotoxic T cells, which identify specific antigen peptides bound to MHC molecules on cell membranes, and Natural Killer (NK) cells, which detect various stress-related markers elevated on cancer cells. Additionally, macrophages act as "clean-up crews," eliminating dead and dying cells from the body, while also assisting in activating T cells to target cancerous cells.

·         Autologous CAR-T cells involve equipping the patient's own T cells with CARs, empowering them to target and eliminate cancer cells. These personalized CAR-T cells undergo further enhancement by removing genes that inhibit immune responses. This combination of CAR integration and immune suppressor gene deletion has shown promising results in eradicating a model of human ovarian cancer in mouse studies. Cartherics has formed a development partnership, CTH-004, with the Peter MacCallum Cancer Centre, and has granted development and commercialization rights to Shunxi for Greater China. Cartherics maintains exclusive rights for development and commercialization of CTH-004 outside of Greater China.

·         Cartherics has created proprietary technology to generate iNK cells from iPSCs, which are highly potent cytotoxic cells capable of targeting various cancer cell types. They have enhanced these cells by genetically modifying the iPSCs to express a cancer-specific chimeric antigen receptor (CAR) and making them resistant to immune function-reducing mechanisms. Currently, the company is focusing on scaling up the manufacturing of these CAR-iNK cells for human trials and expanding its portfolio to include iT cells and iMacrophages. Their primary product, CTH-401, is an iPSC-derived CAR-NK cell therapy targeting TAG-72, a well-established tumor antigen, while also eliminating two genes associated with immune suppression.

·